金城医药：吗啉硝唑氯化钠注射液获药品注册证书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received a drug registration certificate for a new injection, indicating a significant development in its product portfolio and potential market expansion [1] Company Summary - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, has been granted a registration certificate by the National Medical Products Administration for the injection of Morpholine Nitrosyl Sodium [1] - The newly approved drug is indicated for treating infections in adults (≥18 years) caused by sensitive bacteria, which may enhance the company's therapeutic offerings [1] Industry Summary - The approved drug targets several types of infections, including pelvic inflammatory disease caused by Streptococcus and Bacteroides, as well as appendicitis and mixed infections involving anaerobic and aerobic bacteria [1] - This development reflects ongoing advancements in the pharmaceutical industry, particularly in addressing complex bacterial infections [1]